Doctors at Sheba successfully performed a surgery of an inoperable retroperitoneal sarcoma with Helios Cold Plasma Scalpel

Sheba Surgeons Use Pioneering Canady Helios Cold Plasma Scalpel to Remove Inoperable Retroperitoneal Cancer

February 2020 – A team of surgeons at Sheba recently used the Canady HeliosTM Cold Plasma Scalpel (CHCPS) to treat a patient with a rare advanced type of inoperable retroperitoneal sarcoma that had recurred. This innovative surgical tool was developed by US Medical Innovations, LLC (USMI), the first biomedical device company to offer cold plasma for cancer care.

CHCPS is a pioneering device that uses unique plasma gas energy beam technology to simultaneously cut, coagulate, and ablate biological tissue during surgery. It targets and eradicates microscopic cancer cell remnants, while preventing damage to normal healthy cells and tissues.

In August 2019, the Investigational Review Board at Sheba Medical Center issued a one-time pre-market Humanitarian Compassionate-Use Exemption for the cold plasma scalpel. Later that month, a surgical team at Sheba successfully used the revolutionary tool to selectively kill cancerous tissue in a 37-year-old man. The patient was first diagnosed with a rare, inoperable form of retroperitoneal sarcoma at age 20, and the cancer had recurred twice prior to this surgery.

Retroperitoneal sarcoma occurs in the area behind the peritoneum, which is a thin tissue that lines the abdominal area and covers the abdominal organs. The complex surgery at Sheba involved removing the tumor and its adhesion to nearby tissues in the abdomen. Following the procedure, the patient was given intraoperative radiation therapy (IORT) at the site of surgical resection. Cold plasma was then sprayed over the surgical site. The procedure was regarded as successful, and the patient was able to return home to the United States in September 2019.

Aviram Nissan, MD, Chief of General and Oncological Surgery at Sheba, performed the progressive surgery. To help achieve the remarkable outcome, multidisciplinary physicians and healthcare professionals from Sheba teamed with research scientists and engineers from USMI.

“USMI and its sister companies are quite excited about the excellent outcome for the patient,” said Jerome Canady, MD, USMI CEO, Chief Science Officer and Surgeon. “We are equally enthusiastic that CHCPS is approved by the FDA for a multi-center phase I clinical trial Investigational Device Exemption (IDE #G190195).

In February 2020, clinical trials on the Canady Helios Cold Plasma Scalpel (CHCPS) are beginning at Sheba Medical Center and Rush University Medical Center, Chicago, Illinois.